These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2339637)

  • 1. Fluoride pharmacokinetics: its implications in the fluoride treatment of osteoporosis.
    Ekstrand J; Spak CJ
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S53-61. PubMed ID: 2339637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of enteric-coated sodium fluoride tablets as affected by the administration of calcium supplements at different time intervals.
    Devogelaer JP; Nagant de Deuxchaisnes C; Stein F
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S75-9. PubMed ID: 2339640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological availability of Ossin, a sodium-fluoride dragee for osteoporosis therapy].
    Becker R
    Fortschr Med; 1979 Jan; 97(1):39-42. PubMed ID: 759278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of fluoride bioavailability following the administration of sodium fluoride alone and in combination with different calcium salts.
    Briançon D; D'Aranda P; Quillet P; Duplan B; Chapuy MC; Arlot M; Meunier PJ
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S71-3. PubMed ID: 2339639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
    Murray TM; Ste-Marie LG
    CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of terbutaline given in slow-release tablets.
    Nyberg L; Kennedy BM
    Eur J Respir Dis Suppl; 1984; 134():119-39. PubMed ID: 6586473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoride treatment of postmenopausal osteoporosis: age, renal function, and other clinical factors in the osteogenic response.
    Murray TM; Harrison JE; Bayley TA; Josse RG; Sturtridge WC; Chow R; Budden F; Laurier L; Pritzker KP; Kandel R
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S27-35. PubMed ID: 2339633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative bioavailability of fluoride from monofluorophosphate tablets after single oral administration.
    Setnikar I; Maurer H
    Arzneimittelforschung; 1990 Mar; 40(3):323-8. PubMed ID: 2346544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of sodium monofluorophosphate with sodium fluoride and compatibility with calcium.
    Setnikar I; Maurer H
    Arzneimittelforschung; 1990 Sep; 40(9):994-9. PubMed ID: 2080951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of food on relative bioavailability of fluoride in man from Na2FPO3-containing tablets for the treatment of osteoporosis.
    Trautner K
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):242-9. PubMed ID: 2737790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of osteoporosis with a delayed-action sodium fluoride preparation].
    Chlud K
    Z Rheumatol; 1977; 36(3-4):126-39. PubMed ID: 860605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum fluoride level in the NaF treatment of osteoporosis].
    Fuchs C; Dorn D; Hauswaldt C; Henning HV; Köbberling J; Kubosch J; Mc Intosh C; Unger HD; Scheler F
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():910-2. PubMed ID: 1029317
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
    Delmas PD; Dupuis J; Duboeuf F; Chapuy MC; Meunier PJ
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S143-7. PubMed ID: 2339624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis.
    Pak CY; Sakhaee K; Gallagher C; Parcel C; Peterson R; Zerwekh JE; Lemke M; Britton F; Hsu MC; Adams B
    J Bone Miner Res; 1986 Dec; 1(6):563-71. PubMed ID: 3503562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.
    Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):24-6. PubMed ID: 6799412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intermittent therapy with a slow-release fluoride preparation.
    Pak CY; Sakhaee K; Zerwekh JE
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S149-55. PubMed ID: 2339625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement.
    Setnikar I; Rovati LC; Schmid K; Vens-Cappell B; Barkworth MF
    Arzneimittelforschung; 1998 Dec; 48(12):1172-8. PubMed ID: 9893933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets.
    Arnold P; Wermeille M; Chapuy MC; Biollaz J; Grandjean EM; Schelling JL; Meunier PJ
    Bone; 1989; 10(6):401-7. PubMed ID: 2624820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of controlled and sustained release agents in dentistry: a review of applications for the control of dental caries.
    Mirth DB
    Pharmacol Ther Dent; 1980; 5(3-4):59-67. PubMed ID: 6938993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.